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ackground & Aims: Identification of inflamma-
ory bowel disease (IBD) susceptibility genes is key
o understanding pathogenic mechanisms. Re-
ently, the North American IBD Genetics Consor-
ium provided compelling evidence for an associa-
ion between ileal Crohn’s disease (CD) and the
L23R gene using genome-wide association scan-
ing. External replication is a priority, both to
onfirm this finding in other populations and to
alidate this new technique. We tested for associa-
ion between IL23R and IBD in a large independent
K panel to determine the size of the effect and
xplore subphenotype correlation and interaction
ith CARD15. Methods: Eight single nucleotide
olymorphism markers in IL23R tested in the
orth American study were genotyped in 1902 cases
f Crohn’s disease (CD), 975 cases of ulcerative
olitis (UC), and 1345 controls using MassARRAY.
ata were analyzed using 2 statistics, and sub-
roup association was sought. Results: A highly
ignificant association with CD was observed, with
he strongest signal at coding variant Arg381Gln
allele frequency, 2.5% in CD vs 6.2% in controls
P  1.1  1012]; odds ratio, 0.38; 95% confidence
nterval, 0.29–0.50). A weaker effect was seen in UC
allele frequency, 4.6%; odds ratio, 0.73; 95% confi-
ence interval, 0.55–0.96). Analysis accounting for
rg381Gln suggested that other loci within IL23R
lso influence IBD susceptibility. Within CD, there
ere no subphenotype associations or evidence of
nteraction with CARD15. Conclusions: This study
hows an association between IL23R and all sub-henotypes of CD with a smaller effect on UC. This
xtends the findings of the North American study,
roviding clear evidence that genome-wide associ-
tion scanning can successfully identify true com-
lex disease genes.
t is widely recognized that knowledge regarding the
genetic basis of inflammatory bowel disease (IBD) and
ther complex diseases will provide key insights into
athogenic mechanisms. It is this fact that has spurred
fforts to identify disease susceptibility genes. Of the
any complex diseases investigated using molecular ge-
etic techniques, Crohn’s disease (CD) is exceptional in
hat specific genetic variants unequivocally associated
ith disease susceptibility have been successfully identi-
ed.1,2 Nonetheless, characterization of the unknown
umber of remaining CD genes is required to complete
he picture and remains a priority.
CD is one of the 2 common and related forms of IBD,
he other being ulcerative colitis (UC). Within the United
ingdom, they have a combined prevalence of approxi-
ately 4/1000.3 Both are known to have a significant
enetic contribution to their etiology, but this is stronger
or CD than UC.4 The epidemiologic evidence also sug-
ests that CD and UC share some susceptibility genes. In
001, fine mapping of a widely replicated linkage region
n chromosome 16 led to the identification of CARD15
s a major CD susceptibility gene, with mutations lead-
ng to dysregulation of innate immune pathways.1,2
Abbreviations used in this paper: CI, conﬁdence interval; IL23R,
nterleukin 23 receptor; SNP, single nucleotide polymorphism.
© 2007 by the AGA Institute
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1658 TREMELLING ET AL GASTROENTEROLOGY Vol. 132, No. 5ARD15 genes have subsequently been shown in meta-
nalysis to predominantly determine susceptibility to il-
al CD. Variants within a number of other genes have
een associated with CD, UC, or both,5–9 although their
xact roles in IBD susceptibility require clarification and,
n some cases, replication.
To date, pinpointing of disease genes has depended on
etailed evaluation of candidates implicated by their
unction or patterns of expression or by fine mapping
ithin large regions identified in the course of genome-
ide linkage scans. Across the range of common diseases,
roductivity of such approaches has been limited. Most
omplex disease genetic studies, including many in IBD,
ave been beset by poor reproducibility of results and
low progress in identifying disease genes. This has been
ttributed to a range of factors, some of the most impor-
ant being the low resolution of sib-pair linkage analysis,
se of inappropriate statistical thresholds for signifi-
ance, and poor matching of controls due to population
dmixture.10 One powerful new method for the identifi-
ation of complex disease genes is genome-wide associa-
ion scanning, genotyping large panels of affected indi-
iduals and appropriately matched population controls
or hundreds of thousands of polymorphic markers
cross the genome and using appropriately stringent
tatistical thresholds for significance.11 Within the past
ear, such studies have become technically and financially
ossible using sets of markers that capture most of the
ommon variation across the genome using knowledge
egarding human haplotype structure available from the
nternational HapMap Project (http://www.hapmap
org).12 Systematic whole-genome association studies, in
omparison with the previous gold standard of linkage
nalysis, should provide substantially increased power
nd resolution for detection of complex disease suscep-
ibility genes.13
Recently, the results of a 308,332-marker genome scan
n a North American panel of 547 non-Jewish case pa-
ients with CD and 548 controls were reported. Case
atients were selected as having ileal CD to reduce het-
rogeneity.14 Three markers showed a highly significant
ssociation with CD, 2 of which were in CARD15. The
hird marker was a rare coding variant rs11209026c
1142G¡A; Arg381Gln) found in the interleukin 23 re-
eptor (IL23R) gene on chromosome 1 (P 5.05 109).
ine other markers showed association with P  .0001
ither within IL23R or in the intergenic area with the
djacent IL12RB2 gene. Internal replication was achieved
n the index study using both a Jewish CD case-control
ohort (peak P value, 3.36  1013) and family-based
ethodologies, the latter in addition suggesting associa-
ion with UC in a small non-Jewish cohort. This finding
ndicates that IL23R may have a general role in the etiol-
gy of IBD.14
The aims of the current study were to seek replica-
ion of the association between IL23R and IBD in a aarge independent North European cohort represent-
ng the full range of CD and UC phenotypes, examine
n detail genotype-phenotype relationships, explore ev-
dence for epistasis with the known CD susceptibility
ene CARD15, and provide accurate estimates of dis-
ase risk for associated variants. Replication of the
ssociation in an independent cohort would serve 2
mportant purposes. First, it is key to confirming the
eracity of the original finding and the applicability of
hese findings in populations outside North America.
urther, strong independent replication of the key
nding of one of the first published genome-wide
ssociation scans would provide proof of principle that
his novel methodology can be used to identify risk
ariants for complex diseases.
Subjects and Methods
Subjects
A total of 2877 individuals with IBD (1902 with
D and 975 with UC) were recruited in 5 centers across
ngland and Scotland. The study was approved by the
esearch ethics committees at each center.
Standard clinical, radiologic, and histologic diagnostic
riteria were applied.15 Phenotypic details were obtained
y retrospective case notes review. CD phenotype was
lassified by age at diagnosis, location, and behavior of
isease. Only one member of multiply affected families
as included. A total of 1.75% were of Jewish origin, and
.25% were nonwhite. Demographic and subphenotype
ata are presented in Table 1.
Control allele frequencies were obtained from 1345
ndividuals recruited across Britain as part of the 1958
ritish birth cohort.16 Cases and controls were catego-
ized into 12 broad geographical regions within Great
ritain to minimize confounding due to variation in
able 1. Demographic Details of 2877 Individuals With IBD
Used in Case-Control Panel
CD (n  1902) UC (n  975)
edian age at diagnosis (y) 26 38.9
ender (F/M) 1153/745 480/495
moking at diagnosis (%)
Never 58.4 55.0
Ex 9.4 30.3
Current 32.2 14.7
ewish ancestry (%) 1.75 1.9
onwhite (%) 2.25 3.25
urgery (%) 61.8
ocation/extent (%) 32.7 ileal 16.5 rectum only
31.8 colonic 35.0 distal to
35.5 ileocolonic splenic flexure
27.1 perianal 48.5 proximal to
splenic flexure
ehavior (%) 36.5 stenosing
17.15 penetratingllele frequencies across the country.17
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May 2007 IL23R VARIATION IN IBD 1659Genotyping
Genotyping of cases was undertaken with
PLEX chemistry on a matrix-assisted laser desorption/
onization time-of-flight MassARRAY platform (Seque-
om, San Diego, CA). Cases were genotyped for 8
L23R markers reported in the index study, including
he nonsynonymous single nucleotide polymorphism
SNP) rs11209026 encoding amino acid change
rg381Gln (primer sequences in Supplementary Table
; see supplemental material online at www.gastro
ournal.org). Two of the North American markers
rs7517847, rs2201841) were omitted due to their loca-
ion within a sequence of interspersed low-complexity
epeats.
Genotyping of controls was undertaken at the Well-
ome Trust Sanger Institute using the Illumina 550K
hip (Illumina, San Diego, CA). Concordance of geno-
ype calls between the different platforms was con-
rmed by genotyping 87 control DNAs for all 8 mark-
rs using the MassARRAY platform with strong
oncordance of calls between technologies—98.99% for
he 8 markers overall. There was 100% concordance for
markers, including the coding variant Arg381Gln
Supplementary Table 2; see supplemental material
nline at www.gastrojournal.org). The data for 1594
ases of CD genotyped for CARD15 mutations in ear-
ier studies were used to undertake analysis for evi-
ence of interaction between CARD15 and IL23R.18–21
Statistical Methods
Allele frequencies were compared between cases
nd controls and between phenotypic subgroups using 2
ests of 2  2 tables. Odds ratios were calculated for the
inor allele at each SNP; confidence intervals (CIs) were
alculated using Woolf’s method.22 Pairwise SNP linkage
isequilibrium coefficients were estimated using Haplo-
iew.23 Conditional association analysis was imple-
ented using COCAPHASE, a module of the UN-
HASED program.24 This method tests for equality of
dds ratios for haplotypes identical at conditioning loci.
he Mantel–Haenszel test for association conditioning
n geographical region was implemented using PLINK
http://pngu.mgh.harvard.edu/purcell/plink/). Median
able 2. Case-Control Allele Frequencies and Disease Odds
SNP Allele Controls CD P
s1004819 T 0.307 0.383 1.1  108
s10489629 G 0.448 0.372 1.8  108
s11465804 G 0.058 0.025 7.2  1011
s11209026 A 0.062 0.025 1.1  1012
s1343151 T 0.332 0.266 1.1  107
s10889677 A 0.315 0.398 3.4  1010
s11209032 A 0.320 0.390 1.3  107
s1495965 G 0.447 0.517 3.4  107ge at disease diagnosis between groups was compared Csing the Wilcoxon rank sum test. Age at diagnosis was
ichotomized according to the Montreal classification.25
nless specified otherwise, all analyses were performed
sing R version 2.2 for Windows (http://www.R-
roject.org).
Results
All genotypes were in Hardy–Weinberg equilib-
ium in both cases and controls (P  .05). A highly
ignificant association with CD was observed across the
egion (Table 2). The strongest association was observed
t the nonsynonymous SNP Arg381Gln, where the fre-
uency of the A allele was 2.5% in CD compared with
.2% in controls (P 1.11012). The odds ratio for this
rotective allele was 0.38 (95% CI, 0.29–0.50). Alterna-
ively, the common wild-type homozygous GG genotype
an be considered as the risk genotype with an odds ratio
f 2.70. To minimize potential confounding from re-
ional differences in allele frequencies, a Mantel–Haens-
el test was performed across 12 regional strata. Mantel–
aenszel odds ratios was very similar to those obtained
rom pooled data for all SNPs. For example, the Mantel–
aenszel odds ratio was 0.36 (95% CI, 0.25–0.51) for
rg381Gln.
Several SNPs also showed significant association with
C (Table 2). The strongest signal was observed with
ommon SNPs rs1004819 (P .0071) and rs10889677 (P
.0042). The frequency of Arg381Gln was only margin-
lly different between cases and controls (UC, 0.046;
ontrols, 0.062; P .029), with an odds ratio of 0.73 (95%
I, 0.55–0.96). The nonsynonymous SNP Arg381Gln was
n tight linkage disequilibrium with one other SNP
rs11465804, r2  0.85) but weak linkage disequilibrium
ith all 6 other SNPs (r2  0.03–0.1). A separate test for
D association was performed for each SNP condition-
ng on Arg381Gln by conditional regression modeling.
his showed a significant association at all SNPs (P 
001) except rs11465804, with the strongest residual as-
ociation detected at rs10889677 (P  4.6  108).
ence, the nonsynonymous SNP does not account for all
he association signal at this locus.
Data were then analyzed for evidence of significant
enotype-phenotype correlations based on age at onset of
s (95% Confidence Intervals) for CD and UC
ds ratio (95% CI) UC P Odds ratio (95% CI)
.41 (1.23–1.56) 0.348 .00713 1.20 (1.05–1.37)
.73 (0.66–0.82) 0.43 .26 0.93 (0.82–1.05)
.41 (0.31–0.53) 0.046 .081 0.77 (0.58–1.02)
.38 (0.29–0.50) 0.046 .0291 0.73 (0.55–0.96)
.73 (0.65–0.82) 0.315 .26 0.92 (0.81–1.06)
.45 (1.28–1.61) 0.358 .0042 1.22 (1.07–1.39)
.35 (1.22–1.52) 0.3524 .032 1.16 (1.01–1.32)
.32 (1.19–1.47) 0.457 .57 1.04 (0.92–1.18)Ratio
Od
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1660 TREMELLING ET AL GASTROENTEROLOGY Vol. 132, No. 5ignificant subgroup association was observed. In partic-
lar, the subgroup of subjects with CD affecting the
olon only without small bowel disease (n  539) ap-
eared to be as strongly associated as those with exclu-
ively ileal/small bowel involvement (n  668) (minor
llele frequencies, 2.3% and 2.0%, respectively). The age at
isease onset ranged from 12 to 67 years in patients with
D who carried the A allele of Arg381Gln and from 0 to
0 years in wild-type GG cases. There was no difference in
he median age of onset between these 2 groups (AA/AG:
edian, 28 years [n  85]; GG: median, 26 years [n 
650]; P  .26). Stratification of cases by age at diagnosis
ccording to the Montreal classification25 revealed simi-
ar genotype frequencies in all groups (Table 3). For UC,
ubgroup analysis by disease extent, smoking history, and
ex also revealed no significant subgroup association. Age
t onset of UC ranged from 14 to 79 years in cases who
arried the A allele of Arg381Gln and from 2 to 81 years
n wild-type GG cases, with no difference in the median
ge of onset between the 2 groups (AA/AG: median, 34
ears [n  72]; GG: median, 33 years [n  708]; P  .14)
Table 4). A total of 1540 subjects with CD were fully
able 3. Arg381Gln Genotype and Allele Frequencies in CD C
Status
AA AG
ex
Male 1 36
Female 2 49
moking history
No 1 28
Yes 1 21
Ex 0 1
isease location
Pure colorectal disease 1 23
Pure ileal disease 0 31
Ileocolonic disease 1 25
Any colorectal disease 2 46
Any ileal disease 1 54
erianal disease
Yes 2 20
No 1 59
isease behavior
Stenosing 1 32
Penetrating 2 15
Inflammatory only 0 30
urgery
Yes 2 51
No 1 31
ge at diagnosis (y)
16 or younger 1 8
17–40 2 60
Older than 40 0 14
ARD15 statusa
/  3 52
/ 0 15
/ 0 5
Samples are subdivided by CARD15 status into those homozygous w
hose homozygous or compound heterozygous for CD-associated varenotyped for the 3 CARD15mutations (G908R, L1007fs, fi702W) (Table 3). The frequency of Arg381Gln in 460
ases carrying at least one CARD15 mutation (2.2%) was
ot significantly different from that in 1081 cases who
arried none (2.7%; P  .47). None of the 3 cases who
ere homozygous for the rare A allele also carried a
ARD15 mutation.
Discussion
This study provides unequivocal confirmation
f association between variants in the IL23R gene and
BD, suggesting a major effect on overall susceptibility
o CD and a more modest effect on UC. Importantly,
his study also shows the association at IL23R for the
rst time in a non-American population. The strength
f this association at IL23R and the fact that it reaches
uch a magnitude in 2 independent data sets leaves no
oubt that it is a true finding. In addition, this is one
f the first instances of highly significant, independent
eplication of data derived from a genome-wide asso-
iation scan and provides important validation of this
echnique as a hypothesis-free method for the identi-
s Stratified by Known Phenotypic Subgroups and CARD15
GG Total Freq(A)
690 727 0.026
1068 1119 0.024
729 758 0.020
414 436 0.026
127 128 0.004
515 539 0.023
533 564 0.027
642 668 0.020
1101 1149 0.022
1115 1170 0.024
454 476 0.025
1205 1265 0.024
604 637 0.027
248 265 0.036
714 744 0.020
1035 1088 0.025
645 677 0.024
197 206 0.024
1129 1191 0.027
324 338 0.021
1025 1080 0.027
342 357 0.021
98 103 0.024
e (/ ), those heterozygous for CD-associated variants (/), and
(/).ase
ild-typcation of complex disease genes.
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May 2007 IL23R VARIATION IN IBD 1661As with the North American genome-wide scan, the
trongest evidence for association was seen at the non-
ynonymous SNP Arg381Gln, where the frequency of the
allele was 2.5% in CD compared with 6.2% in controls
P  1.1  1012). These allele frequencies are similar to
hose seen in the North American panel.14 There was no
vidence that IL23R variants associate with any particular
ubphenotype of CD based on disease behavior or loca-
ion. Hence, there was no difference in minor allele fre-
uency even between the extremes of pure ileal/small
owel CD and pure colonic CD (2.7% and 2.3%, respec-
ively). Likewise, analysis based on disease behavior did
ot show any specific subgroup associations (Table 3).
his negative result is interesting because it contrasts
ith the other confirmed CD susceptibility locus
ARD15, which seems to have definite associations with
leal disease.26 These findings are extended by the obser-
ation of association with UC overall but not with any
nown UC subphenotype group, suggesting that IL23R
ariants may exert a rather generic effect on chronic
ntestinal inflammation, although the effect size in UC
oes appear to be smaller than in CD. It is noteworthy
hat the odds ratio confidence interval at Arg381Gln for
C (0.73 [95% CI, 0.55–0.96]) does not overlap with that
or CD (0.38 [95% CI, 0.29–0.50]), suggesting a signifi-
antly less marked protective effect of the rare allele for
C compared with CD.
Based on data from our large, independent panel of
D cases, it is possible to provide an accurate estimate of
he size of the effect conferred by IL23R variants with
egard to the risk of CD. We estimated an odds ratio of
.38 (95% CI, 0.29–0.49) for Arg381Gln. This is likely to
e a more accurate estimate than that provided in the
ndex report from the North American study (odds ratio,
.26; 95% CI, 0.15–0.43) due to the well-recognized bias
f the so-called “winner’s curse,” which leads to overes-
imation of effect size in discovery panels.27 Characteriz-
ng the exact effect size is important to permit sample
able 4. Arg381Gln Genotype and Allele Frequencies in UC C
AA A
ex
Male 1 4
Female 2 4
moking history
No 0 2
Yes 0
Ex 1 2
isease extent
Rectum only 1 1
Distal to splenic flexure 1 2
Proximal to splenic flexure 1 4
ge at diagnosis (y)
16 or younger 0
17–40 1 4
Older than 40 0 2ize calculation for any further attempts at replication. (here the effect size is overestimated, there is a risk that
pparently appropriately powered studies will fail to ob-
erve the effect and erroneously conclude that it is a false
ositive.
In some previous reports of genetic association, effect
izes have been quantitated as a population-attributable
isk in addition to the odds ratio. This figure is intended
o estimate the proportion of disease incidence attribut-
ble to a specific variant. However, it cannot be calculated
or a protective minor allele as in the case of Arg381Gln.
urther, while it is possible to think of the effect at
rg381Gln as an increased risk conferred by the common
allele, calculations of population-attributable risk
ased on this assumption lead to an implausibly high
gure due to the very high carriage rate of the G allele in
he control population.
One important question is whether the nonsynony-
ous variant accounts for all of the association signal at
L23R. This was tested by conditional regression model-
ng, looking for evidence of association while controlling
or the effect at Arg381Gln. From this analysis, it is clear
hat there is a strong residual signal, maximal at
s10889677 (P  4.6  108), and hence that variation at
oci in addition to Arg381Gln, either within or adjacent
o IL23R, exert an influence on IBD susceptibility.
hether this reflects a functional impact of the noncod-
ng variants themselves or the fact that they are in linkage
isequilibrium with other functionally significant or cod-
ng variants is yet to be established. Analysis within
aploview (http://www.broad.mit.edu/mpg/haploview/)
f data available from the International HapMap
roject28 (http://www.hapmap.org) shows that this selec-
ion of 8 tag SNPs captures only 18 out of 83 informative
NPs, within IL23R and the 3= intergenic region covered
y these markers, genotyped in the CEPH (Utah residents
ith ancestry from northern and western Europe) panel
t r2  0.8. Any additional coding variation is likely to be
are because interrogation of Ensembl database release 41
s Stratified by Known Phenotypic Subgroups
GG Total Freq(A)
447 489 0.044
436 481 0.049
301 329 0.043
81 88 0.040
160 181 0.061
134 147 0.048
286 311 0.042
387 431 0.052
39 41 0.025
443 485 0.044
228 256 0.055ase
G
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1662 TREMELLING ET AL GASTROENTEROLOGY Vol. 132, No. 5resence of only 2 additional nonsynonymous coding
ariants (rs1884444 and rs7530511) in IL23R with minor
llele frequency 1% in healthy European populations,
oth of which were investigated in the North American
tudy with neither showing evidence of association. How-
ver, it is known that different splice isoforms of IL23R
xist and it is possible that their expression is determined
y some of the documented noncoding variation.29 To
larify these issues, future studies will need to include
esequencing of IL23R in a CD panel and fine mapping
cross the gene using markers identified as a result, as
ell as studies to assess the potential functional impact
f variants identified.
The data with regard to Arg381Gln provide evidence of
very common variant being a disease risk allele, or
onversely protection from CD being conferred by the
are allele. The explanations are likely to be complex but
or immune-mediated conditions may include the fact
hat genetic variation at a particular locus confers a
pectrum of risk, being protective against some diseases,
uch as infections, while increasing the risk of others,
uch as autoimmunity or inflammatory conditions.
hese variations will have been subject to differing selec-
ion pressures in diverse populations as a result of dif-
erent environmental exposures. It is also noteworthy
hat for some of the markers showing evidence of asso-
iation, it is the rarer allele that is associated with in-
reased risk of CD. This further supports the argument
or more than one variant in IL23R with different effects
n gene function.
Recent studies have identified IL-23, the cognate ligand
f IL23R, as a key player in both innate and adaptive
mmune systems. Most IL-23 is secreted by activated
endritic cells, monocytes, and macrophages following
heir exposure to pathogen-derived molecules that bind
t toll-like receptors.30 IL-23 stimulates a unique CD4
elper T-cell population characterized by the production
f IL-17, tumor necrosis factor, and IL-6 and known as
h17 cells. These cells play a central role in driving
utoimmune inflammation in a number of animal mod-
ls. IL-17 stimulates monocytes and endothelial cells to
roduce proinflammatory mediators, which in turn pro-
ote rapid neutrophil recruitment.30 The effect of IL-23
as recently been distinguished from that of the related
eterodimer IL-12, with which it shares a common p40
ubunit.31 Importantly in this regard, 2 studies in knock-
ut mice lacking the p19 subunit of IL-23 showed
arked attenuation of T cell–mediated colitis, while
nockout of the p35 subunit of IL-12 produces no such
ttenuation, suggesting that IL-23 but not IL-12 is essen-
ial for the development of colitis.32,33 The identification
f different roles for IL-12 and IL-23 in control of im-
une pathways together with the current genetic data
uggest that targeting IL-23 (and components of its
ownstream effector pathway) may be a useful and spe-ific strategy to inhibit IBD while sparing systemic host
rotective immunity.34
As well as focusing attention on the IL-23 pathway in
he pathogenesis of IBD, the current study also provides
ey validation of genome-wide association scanning as a
eans of identifying complex disease susceptibility
enes. The North American study group applied an ap-
ropriate, genome-wide significance level, and use of
uch a stringent threshold has immediately led to repli-
ation in our independent panel with a level of signifi-
ance that makes the association indisputable.
To date, complex disease genetic studies have been
eset by poor study design, particularly use of noncon-
ervative thresholds for significance, resulting in publica-
ion of many unreplicated false-positive results across the
pectrum of common disease, hence the importance of
he current study in providing unequivocal early replica-
ion in an independent panel of the principal findings
rom one of the first reported genome-wide association
cans. There are recent reports in another complex dis-
ase (age-related macular degeneration) that also provide
rounds for optimism that this technique produces rep-
icable genetic association data.35–37 The clear message is
hat genome-wide association scanning works and that
his study design, which is being so vigorously applied
cross a number of common diseases, is likely to be
ighly productive. The hope is that with use of appro-
riately stringent statistical thresholds and appropriately
owered data sets, the success seen here in CD will be
enerally applicable without the plethora of false-positive
esults that have vexed the field of complex disease ge-
etics to date.
Appendix
Supplementary Data
Supplementary data associated with this article
an be found, in the online version, at doi:10.1053/j
gastro.2007.02.051.
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